

Outlook Therapeutics, Inc. Logo

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

September 3, 2025

ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- [Outlook Therapeutics, Inc.](#) (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the [EURETINA Innovation Spotlight](#) being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris.

Details for the presentations are as follows:

Session: VEGF Related and Other Retinal Indications

Title: *Optimising the treatment of retinal disease*

Presenter: [Bob Jahr, Chief Executive Officer](#) of Outlook Therapeutics

Date and Time: Wednesday, September 3, 2025, 16:10 PM CEST / 10:10 AM EDT

For more information about this event, please visit [EIS 2025](#).

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to optimize the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Investor Inquiries:

Jenene Thomas

Chief Executive Officer

JTC Team, LLC

T: 908.824.0775

OTLK@jtcir.com



Source: Outlook Therapeutics, Inc.